Mark Livingston Sells 2,517 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,517 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the transaction, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at $1,904,544. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Trading Up 1.5%

Shares of PGNY stock opened at $25.86 on Friday. The firm has a 50-day moving average price of $20.58 and a 200 day moving average price of $22.30. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 33.58, a PEG ratio of 2.28 and a beta of 1.03.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. During the same quarter in the previous year, the company posted $0.17 EPS. The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts predict that Progyny, Inc. will post 1.07 earnings per share for the current year.

Progyny declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 target price on shares of Progyny in a research note on Friday, March 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Citizens Jmp raised their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Hedge Funds Weigh In On Progyny

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny in the 4th quarter valued at about $25,000. Federated Hermes Inc. lifted its stake in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares in the last quarter. Quarry LP lifted its stake in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Progyny in the 2nd quarter valued at about $77,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.